Abstract
Long-term disease-free survival (LT-S) in pts with advanced high grade epithelial OC is poorly described. We recently reported that the 5yr DFS rate was <3% for pts with stage III/IV OC enrolled in 3 large 1st line trials (ESMO 2020). VIVROVAIRE enrolled LT-S OC pts (median DFS:6 yrs) regardless of stage and grade. Here we aimed to characterize the subset in VIVROVAIRE with LT-S and poor prognostic features (stage III/IV and high grade) and compare their immune profile to stage III/IV OC tumors from a neoadjuvant trial (CHIVA) with shorter survival (ST-S).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
